<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of approach to long-term survivors of head and neck cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of approach to long-term survivors of head and neck cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of approach to long-term survivors of head and neck cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert I Haddad, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sewanti Limaye, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Larissa Nekhlyudov, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H590111951">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "cancer survivor" has been used variably in the literature; in general, a cancer survivor refers to any person who has been diagnosed with cancer until the end of life. There are more than half a million survivors who have been rendered cured of head and neck cancer in the United States [
         <a href="#rid1">
          1
         </a>
         ]. The steady increase in the rate of head and neck cancer survivors is likely due to advances in treatment, decrease in smoking rates, and the improved prognosis associated with oropharyngeal carcinomas associated with human papillomavirus (HPV) infection [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">
          "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"
         </a>
         .)
        </p>
        <p>
         This topic will review the long-term issues of survivors of head and neck squamous cell carcinoma (HNSCC), specifically discussing the group of survivors who are without evidence of disease for at least five years [
         <a href="#rid3">
          3,4
         </a>
         ]. Other topics that discuss complications and quality of life in patients following a diagnosis of head and neck cancer are covered separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3369.html" rel="external">
          "Health-related quality of life in head and neck cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H590111957">
         <span class="h1">
          OVERVIEW OF HEAD AND NECK CANCER
         </span>
        </p>
        <p class="headingAnchor" id="H608998309">
         <span class="h2">
          Primary tumor sites
         </span>
         <span class="headingEndMark">
          —
         </span>
         Survivors of head and neck cancer may have been treated for disease arising from one of five anatomic regions of the head and neck. Further details on these specific primary tumor sites are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Anatomic subsites'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The oral cavity (lips, buccal mucosa, anterior tongue, floor of the mouth, hard palate, and upper and lower gingiva)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pharynx (nasopharynx, oropharynx, and hypopharynx)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The larynx (supraglottic, glottic, and subglottic regions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The nasal cavity and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The salivary glands (parotid, submandibular, sublingual, and the minor glands)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1866706729">
         <span class="h2">
          Staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Tumor, Node, Metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the head and neck. TNM staging, which is based on primary tumor site, also impacts prognosis and follow-up in the long-term survivor of head and neck cancer. Further details on the staging of head and neck cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">
          "Overview of treatment for head and neck cancer", section on 'TNM staging system'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H608998315">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of head and neck squamous cell carcinoma (HNSCC) is based on whether the disease is early or advanced stage and the primary site of the tumor. Treatment modalities include surgery, radiation therapy (RT), and systemic therapies. Such treatment may impact prognosis, follow-up, and long-term complications in the survivor of head and neck cancer. Specific discussions for the management of early versus advanced disease by primary site are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">
          "Overview of treatment for head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H590111963">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of HNSCC depends on stage at presentation and the site of involvement.
        </p>
        <p>
         Five-year overall survival in patients with stage I or stage II disease is typically 70 to 90 percent. By contrast, the prognosis for patients who present with more advanced (stage III or IV) disease is poorer. As an example, patients with locoregionally advanced laryngeal carcinoma have an approximately 40 percent overall survival rate at five years. However, in patients with tobacco- and alcohol-related cancers, a 20 percent rate of second malignancy might be expected over five years.
        </p>
        <p>
         For patients with human papillomavirus (HPV) associated locoregionally advanced disease, long-term survival rates are higher than those without HPV associated disease. (See
         <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">
          "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14542126">
         <span class="h1">
          GUIDELINES FOR FOLLOW-UP, SURVEILLANCE, AND SECONDARY PREVENTION IN THE LONG-TERM SURVIVOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the intensity of follow-up is greatest in the first two to four years following diagnosis, since approximately 80 to 90 percent of all recurrences occur within this timeframe. However, patients should continue to be followed beyond five years because of the risk of late complications, as well as the risk of late recurrence or second malignancies. This may be especially important for patients without human papillomavirus (HPV) associated oropharyngeal cancers. (See
         <a class="medical medical_review" href="/z/d/html/3379.html" rel="external">
          "Posttreatment surveillance of squamous cell carcinoma of the head and neck"
         </a>
         .)
        </p>
        <p>
         There are no data to guide the continued follow-up of the long-term head and neck squamous cell carcinoma (HNSCC) survivor. In general, these patients are seen for visits with an oncologist on an annual basis, highlighting the importance of coordinated care.
        </p>
        <p class="headingAnchor" id="H14542057">
         <span class="h2">
          Components of follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         An overview of cancer survivorship for both primary care and oncology clinicians is covered separately. While not specific to HNSCC survivors, the issues discussed are relevant to this population as well. (See
         <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">
          "Overview of cancer survivorship care for primary care and oncology providers"
         </a>
         .)
        </p>
        <p>
         Head and neck cancer survivors should have a detailed cancer-specific follow-up every one to three months for the first year, every two to six months in the second year, every four to eight months during years 3 to 5, and annually beginning five years after the primary treatment. This should include [
         <a href="#rid3">
          3-6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History, including screening for any symptoms that might suggest a local recurrence (eg, new swelling, cough, dysphagia) or metastatic disease (eg, shortness of breath). Other than post-treatment baseline imaging of the primary and the neck if treated, there is no role of routine serial imaging in long-term survivors of head and neck cancer unless otherwise indicated by new signs or symptoms. However, patients with over 20 or more pack-years of smoking history would be candidates for annual low-dose helical computed tomography (CT) scan of the lung. Surveillance for recurrences is based on detailed clinical examination and fiberoptic visualization by the multidisciplinary treatment team. Utilization of imaging for follow-up should be done on a case-by-case basis for high-risk features or clinical indications. (See
         <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">
          "Screening for lung cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The history should also include any interval changes in the social environment (including partner status, life events, living arrangements, and occupational issues), lifestyle factors (eg, smoking and alcohol consumption), and an evaluation of sexual health and body image issues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical exam, including thorough inspection of the head and neck region, and periodic fiberoptic visualization and dental evaluation. (See
         <a class="medical medical_review" href="/z/d/html/3379.html" rel="external">
          "Posttreatment surveillance of squamous cell carcinoma of the head and neck"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with history of radiation therapy to the neck should have serum thyroid-stimulating hormone (TSH) levels every 6 to 12 months due to the risk of hypothyroidism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encouragement of a healthy lifestyle, including assessment of diet and encouragement to remain (or become more) physically active. (See
         <a class="medical medical_review" href="/z/d/html/14222.html" rel="external">
          "The roles of diet, physical activity, and body weight in cancer survivors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encouragement and education about cessation of smoking and the limiting of alcohol consumption for any survivor who continues to partake in either or both. (See
         <a class="local">
          'Smoking and alcohol cessation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Smoking cessation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">
          "Overview of cancer survivorship care for primary care and oncology providers", section on 'Limitation in alcohol consumption'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A speech, hearing, and swallowing evaluation and rehabilitation where clinically indicated should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age-appropriate screening for other malignancies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14542206">
         <span class="h2">
          Smoking and alcohol cessation
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is critical to encourage and educate head and neck cancer survivors about smoking cessation and limiting alcohol consumption [
         <a href="#rid6">
          6,7
         </a>
         ]. Higher rates of secondary cancers are seen in survivors who continue to smoke or consume alcohol [
         <a href="#rid8">
          8,9
         </a>
         ]. In addition, due to the synergistic effects of alcohol and smoking, survivors exposed to both together are at higher risk for recurrence and death. (See
         <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">
          "Overview of cancer survivorship care for primary care and oncology providers", section on 'Risk of subsequent primary cancer'
         </a>
         .)
        </p>
        <p>
         Even light alcohol consumption of less than one drink per day has been shown to be associated with oral cavity, oropharyngeal, and esophageal cancers in a meta-analysis [
         <a href="#rid10">
          10
         </a>
         ]. A study of 165 survivors showed a persistent smoking and alcohol dependence in males, with young age and single status making a special case for referral to formal cessation programs for such patients [
         <a href="#rid11">
          11
         </a>
         ]. Aggressive counseling for lifestyle modification including smoking and alcohol cessation should be provided at each follow-up visit. A combination of behavioral support and pharmacologic therapy may be needed. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">
          "Alcohol use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110403371">
         <span class="h2">
          Diet and exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifestyle changes including diet and exercise have a significant impact on quality of life and secondary prevention in survivors. Pretreatment dietary counseling may help in improving long-term outcomes for survivors and could involve simple phone-based counseling for patients starting therapy [
         <a href="#rid12">
          12
         </a>
         ]. In a meta-analysis of cancer survivors, the highest adherence score to a Mediterranean diet was significantly associated with a lower risk of all-cause cancer mortality (relative risk [RR] 0.87, 95% CI 0.81-0.93), also seen in head and neck cancer (RR 0.40, 95% CI 0.24-0.66) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Exercise and physical activity in head and neck cancer survivors has been associated with improved quality of life and should be encouraged and incorporated in their counseling process [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14222.html" rel="external">
          "The roles of diet, physical activity, and body weight in cancer survivors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H590111975">
         <span class="h1">
          LATE AND LONG-TERM COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Much of our understanding of the issues in head and neck squamous cell carcinoma (HNSCC) survivors comes from evaluations of patients followed for two to three years after treatment, although there are several landmark papers describing issues of long-term survivors [
         <a href="#rid16">
          16-21
         </a>
         ]. As a result, there are little data to inform the issues experienced in long-term HNSCC survivors who are without evidence of disease for five years or more. However, they are at an increased mortality due to cancer and other causes, which persists for up to 10 years after diagnosis. As an example, one study evaluated almost 36,000 HNSCC survivors followed for a median of 7.7 years after initial diagnosis (range, 3 to 17.9 years) [
         <a href="#rid22">
          22
         </a>
         ]. The rates of death at 5 and 10 years were 15.4 and 41 percent, respectively. Causes of death during follow-up consisted of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HNSCC (29 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second primary malignancy (23 percent) with the most common malignancies being primaries of the lung (53 percent), esophagus (10 percent), and colorectal origin (5 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular disease (21 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung disease such as chronic obstructive pulmonary disease, pneumonia, and influenza (23 percent)
        </p>
        <p>
        </p>
        <p>
         These data highlight the importance of follow-up, which should be coordinated between oncology and primary care. (See
         <a class="local">
          'Coordination of care and specialist referral'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14541816">
         <span class="h2">
          Head and neck toxicity
         </span>
        </p>
        <p class="headingAnchor" id="H608998956">
         <span class="h3">
          Dental complications and oral health
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oro-dental care and follow-up are very important, especially after radiation therapy (RT) to the head and neck area. Poor oral health has been linked with inferior survival and worse outcomes [
         <a href="#rid23">
          23,24
         </a>
         ]. Worsening of dental health after treatment is common and could lead to significant compromise in quality of life of long-term head and neck cancer survivors. Deterioration of dental and oral health is thought to be secondary to xerostomia, change in salivary pH to acidic, demineralization, and decreased vascularity associated with radiation [
         <a href="#rid16">
          16,25
         </a>
         ]. Gradual dental decline, xerostomia and difficulties with ill-fitting dentures, coupled with the financial limitations including the lack of proper dental insurance coverage, can add to the burden of long-term survivors. In addition, inadequate dental rehabilitation results in a compromised ability to eat and has been directly linked to poor quality of life due to compromised eating and chronic pain [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Although data on the late effects of mucositis are limited, the patient’s dental status at one year post-treatment appears to be a strong predictor of quality of life of survivors five years from completion of therapy [
         <a href="#rid17">
          17
         </a>
         ]. The incidence of dental caries increases 50-fold after RT and is seen at a rate of 2.5 per month [
         <a href="#rid25">
          25,26
         </a>
         ]. They are often highly destructive and lead to extractions and osteoradionecrosis in up to 15 percent of irradiated head and neck cancer patients [
         <a href="#rid27">
          27,28
         </a>
         ]. Dental status was found to have a direct impact on eating in public, chewing, swallowing, and normalcy of diet [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Patients undergoing RT for head and neck cancers may develop mucosal atrophy and telangiectasias, and may experience chronic mucosal pain and sensitivity [
         <a href="#rid29">
          29
         </a>
         ]. Patients often describe the mucosal pain as a burning or a scalded sensation that may represent neuropathy. Hot and/or spicy and acidic foods and dry air reportedly exacerbate symptoms. Mucosal sensitivity may permanently alter food choices in this population.
        </p>
        <p>
         Management emphasizes attention to the risk factors of hyposalivation, mucosal infection, and the neuropathic components of pain associated with mucositis [
         <a href="#rid29">
          29
         </a>
         ]. Timely dental rehabilitation including dental restoration and dental prosthesis development and fitting may help improve quality of life of survivors. Our approach is consistent with the guidelines from the Department of Veterans Affairs and the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid3">
          3,30
         </a>
         ]. Further discussion on the oral complications and treatment guidelines for cancer survivors is covered separately. (See
         <a class="medical medical_review" href="/z/d/html/16346.html" rel="external">
          "Oral health in cancer survivors", section on 'Approach to the cancer patient'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H590111981">
         <span class="h4">
          Xerostomia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xerostomia or dry mouth is common in most head and neck cancer survivors who have undergone radiation as a part of their treatment. It remains one of the main late complications of RT and a leading cause of compromise of quality of life of head and neck cancer survivors. There can be gradual recovery of some salivary secretion over time, with maximum recovery one to two years post-therapy [
         <a href="#rid31">
          31-37
         </a>
         ], but this depends on the total radiation dose to the gland tissue. Xerostomia is a long-lasting and frequently permanent problem that adversely impacts quality of life, even years after diagnosis.
        </p>
        <p>
         In long-term survivors (more than five years following treatment), symptoms of xerostomia can include dry mouth, sticky saliva, persistent need to drink water or fluids while eating, swallowing and speaking, difficulty eating and speaking, early dental decline, and poor oral health [
         <a href="#rid18">
          18,19
         </a>
         ]. In one study, xerostomia was present in 64 percent of long-term survivors at a mean follow-up of 9.6 years following RT [
         <a href="#rid20">
          20
         </a>
         ]. There is decreased rate of xerostomia with intensity-modulated radiation therapy (IMRT). In a study of long-term quality of life of head and neck survivors at five years after IMRT, nearly 84 percent of survivors reported saliva "of normal consistency" or "less saliva than normal but enough," and only 16 percent reported "too little saliva" [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3385.html" rel="external">
          "Overview of the treatment of locoregionally advanced head and neck cancer: The oropharynx", section on 'Radiation schedule and technique'
         </a>
         .)
        </p>
        <p>
         The management of xerostomia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Salivary gland damage and xerostomia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H608999335">
         <span class="h4">
          Osteoradionecrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoradionecrosis can be seen in patients needing dental restorations or extractions in previously radiated areas [
         <a href="#rid39">
          39,40
         </a>
         ]. The incidence of osteoradionecrosis with conventional RT or IMRT is in the range of 5 to 7 percent. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Osteoradionecrosis and soft tissue necrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16346.html" rel="external">
          "Oral health in cancer survivors", section on 'Osteonecrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H608999341">
         <span class="h4">
          Trismus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trismus or lockjaw could occur in up to 35 percent of head and neck cancer patients following RT and in patients treated with surgery [
         <a href="#rid41">
          41,42
         </a>
         ]. However, these estimates appear to be lower for patients treated with IMRT (5 to 15 percent) [
         <a href="#rid41">
          41,43
         </a>
         ]. More commonly seen after oral cavity, oropharyngeal, and nasopharyngeal cancer therapy, trismus is caused by inflammation and fibrosis of the pterygoid and masseter muscles. It has an important repercussion on quality of life and could lead to poor dental hygiene, worsening xerostomia, and dental complications [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Active and passive exercise should be initiated as soon as post-treatment fibrosis becomes evident because if left untreated, it may impact the range of jaw movement. Unfortunately, once there is restriction clinically evident it is difficult to reverse.
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          Pentoxifylline
         </a>
         and botulinum toxin have been used to treat established trismus in long-term survivors with some evidence of a symptomatic benefit, although no objective improvement of trismus was seen [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16346.html" rel="external">
          "Oral health in cancer survivors", section on 'Trismus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Trismus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2827.html" rel="external">
          "Physical rehabilitation for cancer survivors", section on 'Trismus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H590111993">
         <span class="h3">
          Dysphagia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated for HNSCC can experience dysphagia during treatment and as both an acute and long-term complication. Speech and swallowing impairment are seen in over 50 percent of head and neck cancer patients even before the start of treatment [
         <a href="#rid46">
          46
         </a>
         ]. In addition, impaired speech and swallow function are common after oral or oropharyngeal surgery and in over 50 percent of patients undergoing partial laryngectomy [
         <a href="#rid47">
          47,48
         </a>
         ]. Subsequent malnutrition and unintended weight loss can also exacerbate dysphagia due to a reduction in the will to eat and a more global psychological toll on the patient.
        </p>
        <p class="headingAnchor" id="H2213071010">
         <span class="h4">
          Causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of factors may result in or worsen dysphagia in long-term survivors of head and neck cancer, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of normal anatomic structures and/or altered relationships between normal structures (eg, loss of the hard palate or part of the larynx)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation-induced xerostomia and fibrosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Problems with dentition
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trismus
        </p>
        <p>
        </p>
        <p>
         Dysphagia may also result as a consequence of esophageal stenosis, which can occur as a late complication of progressive RT-related fibrosis. The rate of long-term grade 3 esophageal strictures appears to be higher for patients treated with IMRT and is thought to be due to a greater dose of radiation to pharyngeal constrictor muscles [
         <a href="#rid49">
          49,50
         </a>
         ]. As an example, the rates of a pharyngoesophageal stricture with IMRT and conventional RT were 16.7 and 5.7 percent, respectively [
         <a href="#rid50">
          50
         </a>
         ]. However, in another study of patients with nasopharyngeal carcinoma, late toxicity was significantly less severe with IMRT-based therapy rather than non-IMRT-based therapy, including neuropathy, hearing loss, dysphagia, xerostomia, and neck fibrosis [
         <a href="#rid51">
          51
         </a>
         ]. In preliminary results from one phase III trial (DARS), dysphagia-optimized IMRT improved patient-reported swallowing functions [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H296874319">
         <span class="h4">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop an esophageal stricture may present with subtle or significant complaints, including dysphagia (eg, feeling "something getting stuck in the throat/chest") or changing patterns of cough when swallowing food, indicating possible episodes of aspiration. New symptoms or other more subtle changes in a patient’s normal swallowing pattern should warrant a work-up to rule out esophageal stenosis, especially if these symptoms are persistent. (See
         <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">
          "Approach to the evaluation of dysphagia in adults", section on 'Approach to diagnostic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H366420376">
         <span class="h4">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even for patients who present with longstanding dysphagia, we believe there is a role for cancer rehabilitation, including speech and language therapists. Therapy consisting of swallowing exercises and maneuvers, neuromuscular stimulation, and education regarding the importance of lifestyle modification (eg, changing the food consistency to prevent aspiration) can help prevent worsening (or more significant) morbidity. Speech and swallow rehabilitation is an inherent part of the multidisciplinary team involved in treatment. The rehabilitation services are freely available in the community as well. Dysphagia as a late complication of HNSCC treatment and the role of rehabilitation is covered separately. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Dysphagia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3368.html" rel="external">
          "Speech and swallowing rehabilitation of the patient with head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1824632188">
         <span class="h4">
          Feeding tube utilization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite preventive measures employed prior to and/or during treatment, 10 to 25 percent of HNSCC survivors become feeding tube-dependent for life [
         <a href="#rid19">
          19,53
         </a>
         ]. This is seen in survivors with compromised oral cavity function due to treatment or those who have had multiple episodes of aspiration. The psychosocial burden of clinically significant dysphagia should be recognized and patients referred for counseling and support in order to prevent depression and distress in survivors (and in their caregivers).
        </p>
        <p class="headingAnchor" id="H14541890">
         <span class="h2">
          Neuromuscular toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several neuromuscular complications may occur in long-term HNSCC survivors. These include: speech difficulties, chronic pain, ototoxicity, and/or peripheral or autonomic neuropathies. These are discussed below.
        </p>
        <p class="headingAnchor" id="H2241433456">
         <span class="h3">
          Speech intelligibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Speech and articulation could be significantly impaired after treatment for oral cavity cancer, floor of the mouth or alveolar crest cancers, cancers requiring mandibular resection, and with total or partial glossectomy [
         <a href="#rid54">
          54-56
         </a>
         ]. Voice and phonation issues affect patients with laryngeal cancer treated with chemoradiation and patients who have had a laryngectomy [
         <a href="#rid57">
          57
         </a>
         ].
         <strong>
         </strong>
         (See
         <a class="medical medical_review" href="/z/d/html/3368.html" rel="external">
          "Speech and swallowing rehabilitation of the patient with head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1824629140">
         <span class="h4">
          Due to complications of total laryngectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although long-term survivors are usually acclimated to the surgical outcomes, total laryngectomy continues to impart a high impact on quality of life of survivors even years after surgery [
         <a href="#rid58">
          58
         </a>
         ]. Despite a multidisciplinary follow-up, long-term rehabilitation with these prostheses could be difficult and require guidance and support [
         <a href="#rid59">
          59
         </a>
         ]. For patients who undergo voice rehabilitation with tracheoesophageal voice prosthesis, leakage from the site may add to long-term morbidity [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Lack of motivation, discouragement, depression, and continued need for lifestyle modification could have a cumulative impact on long-term survivors. Providers should be aware of the difficulty that can be experienced postlaryngectomy and provide continued support, counseling, and specialized care wherever needed. (See
         <a class="local">
          'Psychosocial issues of the caregivers'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1824629146">
         <span class="h4">
          Due to recurrent laryngeal nerve palsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent laryngeal nerve palsy could occur as a rare late complication of head and neck radiation (mostly reported with conventional RT) leading to delayed mobility of vocal cord(s) and hoarseness [
         <a href="#rid62">
          62,63
         </a>
         ]. It could lead to voice strain and speech unintelligibility in survivors several years from completion of therapy that could be frustrating. Speech rehabilitation and Botulinum injection in the vocal cords have limited benefit with temporary results, and lifestyle modification may be the only option in some cases [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Speech therapy is required to improve speech intelligibility. Advances in reconstructive surgical techniques with tissue transfer, mandibular plates, and palatal prosthesis have been helpful [
         <a href="#rid65">
          65-67
         </a>
         ]. Voice therapy is indicated in patients with hoarseness and problems with phonation after chemoradiation for glottic cancer [
         <a href="#rid68">
          68
         </a>
         ].
         <strong>
         </strong>
         Speech rehabilitation after total laryngectomy could be challenging and requires motivation and perseverance. It could involve an artificial larynx, transesophageal puncture, or esophageal voice production [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2549252238">
         <span class="h3">
          Chronic pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic pain (including somatic, neuropathic, and neuralgic pain) involving the head or neck after treatment can be debilitating and is reported in some cancer survivors over five years post-treatment [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Chronic pain has been known to contribute to functional limitation and employment in survivors. In one study, nearly 40 percent of unemployed long-term survivors reported being in chronic pain [
         <a href="#rid72">
          72,73
         </a>
         ]. In another observational study, chronic systemic symptoms, were noted in nearly 50 percent of head and neck cancer survivors at one year post-treatment completion, such as chronic widespread pain, fatigue, sleep disturbance, mood disorders, neuropsychiatric symptoms, and temperature dysregulation [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Although there are limited data beyond five years post-treatment, in one study, nearly 18 percent of head and neck survivors complained of chronic pain as a long-term effect of prior cancer-related treatment [
         <a href="#rid17">
          17
         </a>
         ]. In this study, chronic pain, type of diet, and dental status at one year were strongly predictive of quality of life of these survivors at the five-year post-treatment time point. However, in a different study, the mean chronic pain scores (measured using the Head and Neck Cancer Inventory social disruption scores) showed there was no difference in pain scores among those who had received chemoradiation versus surgery followed by adjuvant radiation-based therapy [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Among the more recognized pain syndromes, shoulder and neck pain are two recognizable neuropathic conditions, particularly for those who underwent a neck dissection. Efforts to understand other specific pain predilections in long-term survivors are ongoing.
        </p>
        <p>
         Interventions with drugs like
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , utilization of pain management services for treatment with narcotics and behavioral therapy, and incorporation of physical therapy may all be needed for appropriate pain control. Acupuncture has been shown to reduce pain and shoulder dysfunction after neck dissection [
         <a href="#rid75">
          75
         </a>
         ]. Long-term opioid use and dependence is a well-described phenomenon and was noted in approximately 7 percent of long-term head and neck cancer survivors at one year post-treatment completion [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2827.html" rel="external">
          "Physical rehabilitation for cancer survivors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1390.html" rel="external">
          "Overview of the clinical uses of acupuncture"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2792.html" rel="external">
          "Cancer pain management: General principles and risk management for patients receiving opioids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H608999562">
         <span class="h3">
          Ototoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and radiation could lead to compromise in hearing. Cisplatin-induced ototoxicity is well-recognized and is known occur as a result of cisplatin-induced damage of the outer hair cells of cochlea. Radiation to the cochlea has been known to induce sensory neural hearing loss. Cisplatin given concurrently with radiation lowers the dose of radiation that can cause hearing loss. The incidence ranges from 20 to 40 percent at one year post-treatment with IMRT to over 40 percent at 5 years with conventional RT [
         <a href="#rid77">
          77,78
         </a>
         ]. The interindividual variation in the degree of cisplatin-induced toxicity endured is thought to be dependent on polymorphisms in the glutathione-S-transferases and other genetic variations [
         <a href="#rid79">
          79
         </a>
         ]. For such cases, hearing augmentation may be required to improve quality of life and functioning. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H608999635">
         <span class="h3">
          Peripheral neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term survivors may have to deal with residual peripheral neuropathy, both from
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and taxanes. Peripheral neuropathy of some degree could be seen in over 80 percent of patients who have received 300 mg/m
         <sup>
          2
         </sup>
         of cumulative dose of cisplatin [
         <a href="#rid80">
          80
         </a>
         ]. The neuropathy usually improves over time, but complete resolution is rarely seen [
         <a href="#rid81">
          81
         </a>
         ]. No preventative strategy has been of benefit as per an analysis [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H608999703">
         <span class="h3">
          Autonomic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autonomic dysfunction usually presents as dizziness and near syncope, and it has been reported in long-term survivors, especially for those who received RT to the neck [
         <a href="#rid83">
          83
         </a>
         ]. RT induces inflammation of the intimal layer, which is thought to result in fibrosis of the arterial walls of the neck. This is thought to contribute to the stiffening of the carotid sinus baroreceptors leading to decreased baroreceptor sensitivity, which causes blood pressure lability, including the onset of orthostasis-like phenomenon causing near syncope or syncope like events [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         For patients with autonomic dysfunction, baroreceptor sensitivity may be improved with exercise, particularly in older patients with a sedentary lifestyle [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14541923">
         <span class="h2">
          Musculoskeletal complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphedema involving the neck may present as a late complication, especially in patients who underwent a neck dissection or RT. In addition, neck stiffness is a common complaint that is encountered in clinic.
        </p>
        <p class="headingAnchor" id="H4081389933">
         <span class="h3">
          Lymphedema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphedema of the neck is common, although poorly recognized and reported [
         <a href="#rid85">
          85,86
         </a>
         ]. It could occur after surgery or RT to the head and neck area. Although lymphedema generally resolves with time, chronic lymphedema, if severe, could lead to permanent neck stiffness and disfigurement. Edema of the larynx and the pharynx could also be severe and cause airway obstruction and dysphagia [
         <a href="#rid85">
          85,87
         </a>
         ].
        </p>
        <p>
         Although late-onset neck lymphedema is not well-studied, it is not uncommon for long-term head and neck survivors to present with acute lymphedema. In one study evaluating patients with neck lymphedema, the median time to onset of symptoms measured from the time of treatment completion was 17 months. However, the authors did not solely evaluate long-term survivors; they included patients who presented with neck lymphedema between 3 and 156 months (13 years) of treatment completion [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         Early institution of complete decongestive therapy is indicated. In our experience, it can provide quick relief of symptoms and prevent chronic complications [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/738.html" rel="external">
          "Clinical staging and conservative management of peripheral lymphedema", section on 'Complete decongestive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2876871808">
         <span class="h3">
          Neck stiffness
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our experience, neck stiffness is one of the more common chronic complaints of patients in long-term follow-up. Neck stiffness is usually caused by fibrosis of the neck muscles as a result of the longstanding effects of RT and/or neck surgery, and it is most common in patients who received both these treatment modalities [
         <a href="#rid89">
          89-91
         </a>
         ].
        </p>
        <p>
         Neck stiffness significantly impacts quality of life among head and neck cancer survivors [
         <a href="#rid92">
          92
         </a>
         ]. Unfortunately, there are limited clinical studies addressing the treatment of neck stiffness. Physical therapy is the standard of care. Various regimens have been proposed, but all have demonstrated limited clinical benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical therapy
         </strong>
         – For patients with neck stiffness, physical therapy is useful, even for late symptoms. Physical therapy should be pursued with a therapist experienced in the treatment of radiation fibrosis [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Botulinum toxin
         </strong>
         – As with trismus, botulinum toxin has been utilized to reduce symptoms from radiation-induced fibrosis in long-term survivors and may be applicable to neck stiffness, spasms, discomfort, and pain [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          Pravastatin
         </a>
         <strong>
         </strong>
         – In a single-arm phase II clinical trial of pravastatin (40 mg daily for 12 months), an at least 30 percent reduction of chronic radiation-induced fibrosis was seen in 15 of 42 patients (36 percent) [
         <a href="#rid94">
          94
         </a>
         ]. Patients reported improved quality of life and minimal toxicities (myalgias and esophagitis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other treatment options include hyperbaric oxygen and
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         with
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Additional information about radiation-induced fibrosis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7055.html" rel="external">
          "Clinical manifestations, prevention, and treatment of radiation-induced fibrosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1408966754">
         <span class="h2">
          Neurocognitive effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT and chemoradiotherapy as components of definitive therapy for head and neck cancer have been postulated to have effects on the central nervous system and result in neurocognitive deficits [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         The risk of neurocognitive impairment was prospectively studied in a cohort of 80 patients undergoing definitive treatment for nonmetastatic squamous cell carcinoma of the head and neck and in 40 controls without cancer [
         <a href="#rid96">
          96
         </a>
         ]. All patients received RT, 86 percent received systemic therapy (most with a platinum-based regimen), and 76 percent had a primary oropharyngeal carcinoma. Neurocognitive function was assessed at baseline, 6, 12, and 24 months using a cognitive battery assessing multiple domains. Progressive impairment in global cognitive function was observed in 22 of 58 patients (38 percent) at 24 months, but in 0 of 40 controls (0 percent).
        </p>
        <p>
         Despite these studies, there are limited data confirming the degree of deficit and time to recovery. In clinical settings, it is important to take into consideration reversible causes for decline such as depression and to discriminate verbal decline due to lack of appropriate orodental rehabilitation from neurocognitive decline. Brain-sparing IMRT is now being used to help reduce the cognitive decline post-head and neck cancer therapy.
        </p>
        <p class="headingAnchor" id="H14541930">
         <span class="h2">
          Damage to the carotid arteries
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following treatment of HNSCC, patients have an increased risk of stroke. However, there are no screening mechanisms in place for head and neck cancer survivors. Therefore, the prevention and management of stroke in long-term HNSCC survivors is similar to the approach to the general population and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Carotid artery injury'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14541937">
         <span class="h2">
          Nephrotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some degree of nephrotoxicity is seen in up to 30 percent of patients treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         [
         <a href="#rid97">
          97
         </a>
         ]. Cisplatin has been known to damage the proximal and distal tubular epithelium and collecting ducts in animals and humans [
         <a href="#rid98">
          98
         </a>
         ]. Elevated creatinine levels, hypomagnesemia, hypokalemia, hypocalcemia, occasionally sodium wasting, proteinuria, and albuminuria could all be seen in different combinations in long-term survivors [
         <a href="#rid99">
          99,100
         </a>
         ]. Fortunately, long-term follow-up of patients exposed to cisplatin indicates that renal function remains stable or slightly improves over time. (See
         <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">
          "Cisplatin nephrotoxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14541944">
         <span class="h1">
          PSYCHOSOCIAL ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H608999737">
         <span class="h2">
          Sexual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term survivors may experience difficulty with sexual function. This may have an anatomic basis (eg, chemotherapy-induced peripheral neuropathy) or a more complex etiology related to intimacy issues and psychologic distress. (See
         <a class="medical medical_review" href="/z/d/html/17009.html" rel="external">
          "Overview of sexual dysfunction in female cancer survivors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100080.html" rel="external">
          "Overview of sexual dysfunction in male cancer survivors"
         </a>
         .)
        </p>
        <p>
         Short-term studies indicate that sexual dysfunction can be an important consequence of treatment for head and neck cancer. In a study of 262 patients with oral squamous cell carcinoma, 34 percent did not have sex at all in the six months following diagnosis, compared with 10 percent in the six months prior to diagnosis [
         <a href="#rid101">
          101
         </a>
         ]. This change was present in all patients, regardless of whether they had human papillomavirus (HPV) associated disease. A persistence of dissatisfaction with sexual function was reported in another series at 12 months after treatment [
         <a href="#rid102">
          102
         </a>
         ]. Unfortunately, there is a lack of data for longer-term survivors of head and neck squamous cell carcinoma (HNSCC).
        </p>
        <p>
         Although sexuality is a key issue with head and neck cancer survivors, minimal attention has been given to it over time. Alterations in self-image, disfigurement, change in oral sensation and odor, anxiety, and depression have been thought to contribute. Chemotherapy could lead to altered sensation, arousal, and erectile dysfunction in men. Issues related to transmission of HPV to a spouse or partner may add a significant burden to a relationship. A clear understanding of the issues related to HPV and its transmission is crucial [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H608999743">
         <span class="h2">
          Body image issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Facial disfigurement, loss or change of organ function, fear of recurrence, death, and revised self-image could all prove challenging to adjustment. Body image reintegration and adjustment are thought to happen over time and require compassion, patience, and encouragement from the family, friends, and the treating clinician.
        </p>
        <p>
         In a report from a larger study of body image among 280 HNSCC patients who underwent surgery, and who were less than one month to more than five years from diagnosis, over 50 percent of patients reported concerns regarding body image at the time of assessment [
         <a href="#rid104">
          104
         </a>
         ]. Major issues that can lead to social avoidance include limitations with speech and swallowing and concerns regarding appearance and disfigurement.
        </p>
        <p>
         Poorer quality of life scores have been reported in the setting of body image dysfunction [
         <a href="#rid105">
          105
         </a>
         ]. In another study that evaluated the aesthetics in long-term survivors, moderate to severe pain, minimal oral intake, and being edentulous at one year from treatment were associated with significantly low aesthetics scores at five years [
         <a href="#rid17">
          17
         </a>
         ]. In a similar report by the same group, long-term survivors who had received chemoradiation-based therapy had better aesthetics scores than the surgically treated group at five years from treatment [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H590112101">
         <span class="h2">
          Depression, anxiety, and suicide risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anxiety and depression are common in head and neck cancer patients before and after completion of therapy and have been reported in nearly 30 percent of survivors at five years from completion of therapy [
         <a href="#rid17">
          17,106
         </a>
         ]. Clinicians should regularly assess for such mental health conditions in long-term survivors to ensure that patients receive the support necessary [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109569.html" rel="external">
          "Patients with cancer: Clinical features, assessment, and diagnosis of unipolar depressive disorders"
         </a>
         .)
        </p>
        <p>
         In one study of head and neck cancer survivors, factors that predicted depression included the presence of a tracheostomy tube or laryngeal stoma, gastrostomy tube dependence, and continued smoking at the time of follow-up [
         <a href="#rid21">
          21
         </a>
         ]. Additional studies have identified comorbid psychiatric illness, long-term toxicity of treatment, as well as use of alcohol and/or drugs to cope with the diagnosis as risk factors for depression and suicide [
         <a href="#rid107">
          107,108
         </a>
         ].
        </p>
        <p>
         While several psychosocial parameters may improve with the passage of time from diagnosis, in one study, anxiety persisted and became more pronounced in survivors greater than five years from diagnosis [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         Survivors of head and neck cancer have an increased rate of suicide [
         <a href="#rid107">
          107,108,110,111
         </a>
         ]. One analysis using the Surveillance, Epidemiology, and End Results (SEER) database reported a suicide rate in this population of 63 suicides per 100,000 person-years [
         <a href="#rid108">
          108
         </a>
         ]. When compared with survivors of other cancers as a whole, head and neck cancer survivors were approximately two times more likely to commit suicide; only pancreatic cancer survivors had a higher suicide rate than this population.
        </p>
        <p>
         In a prospective study of 223 consecutive patients with newly diagnosed head and neck cancer followed for one year, 16 percent were suicidal, 0.9 percent attempted suicide, and 0.4 percent committed suicide [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         These studies illustrate the severity of depression and suicide, which are two of the most concerning long-term sequelae of head and neck cancer treatment.
        </p>
        <p class="headingAnchor" id="H1826633185">
         <span class="h2">
          Employment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 50 percent of head and neck survivors were reported as being disabled from disease at the two-year post-treatment time point [
         <a href="#rid72">
          72,112
         </a>
         ]. Unfortunately, data are limited in longer-term survivors.
        </p>
        <p>
         Despite this, a number of reasons have been reported for the continued disability of HNSCC survivors, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term oral dysfunction, loss of appetite, deterioration in social functions, and high anxiety levels [
         <a href="#rid113">
          113
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More advanced stage at original presentation, alcohol use, and lower educational levels [
         <a href="#rid112">
          112
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Survivors may also face challenges related to facial disfigurement, limitations in speech intelligibility, dietary limitation, and rarely even dependence on enteral tube feeding. These issues could lead to low self-esteem, lack of initiative in socializing and competing with peers, limitations in employment opportunities, and growth at work place. In a study of 208 head and neck cancer survivors, socioeconomic factors and comorbidities were found to be important predictors of quality of life [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2832633276">
         <span class="h2">
          Psychosocial issues of the caregivers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychosocial adjustments of survivors and their caregivers are intimately linked [
         <a href="#rid115">
          115,116
         </a>
         ]. Active counseling of the patient and family members during and after treatment play an important role in minimizing the psychosocial burden and help in rehabilitation. Long-term help and support should be provided to caregivers and family in situations where survivors have multiple long-term complications of treatment. The care of a head and neck cancer survivor could still be very involved in cases with feeding tube, tracheotomy, and other disabilities like compromised speech intelligibility.
        </p>
        <p class="headingAnchor" id="H1515497753">
         <span class="h1">
          SUBSEQUENT PRIMARY CANCERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subsequent primary cancers have been reported in up to 20 percent of head and neck cancer survivors and are related to smoking and alcohol exposure. For those who develop a subsequent primary cancer, prognosis is generally poor, with a median overall survival typically around 12 months [
         <a href="#rid117">
          117
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">
          "Overview of cancer survivorship care for primary care and oncology providers", section on 'Risk of subsequent primary cancer'
         </a>
         .)
        </p>
        <p>
         During the last 20 years, a clear decrease in the incidence of subsequent cancers in primary oropharyngeal tumors has been observed. This has been associated with an increasing incidence of human papillomavirus (HPV) associated oropharyngeal carcinomas [
         <a href="#rid118">
          118
         </a>
         ]. With emerging data about difference in sexual practices of patients with HPV associated tumors, longitudinal follow-up is warranted [
         <a href="#rid118">
          118,119
         </a>
         ].
        </p>
        <p>
         Lifestyle modification, smoking, and alcohol cessation intervention programs are needed to help cancer survivors reduce their risks for a second primary [
         <a href="#rid9">
          9
         </a>
         ]. Patients should be counseled for smoking and alcohol cessation routinely and aggressively. (See
         <a class="local">
          'Smoking and alcohol cessation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H433152071">
         <span class="h1">
          COORDINATION OF CARE AND SPECIALIST REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Care must be taken to communicate the plan of care and follow-up with the general medical provider or primary care clinician. A detailed communication of the plan of care with the primary dentist is also essential. In a study of oncologists and primary care physicians, the lack of clarity of who provides specific aspects of psychosocial care to cancer survivors brought to attention the need for better survivorship care coordination with the multidisciplinary head and neck oncology team [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
         Head and neck cancer survivors have to engage in intensive self-management protocols for oral care; skin care; complex drug schedules and delivery; complicated instrument care (eg, tracheostomy care and feeding tube care); and intense rehabilitation programs like oral-dental rehabilitation, speech and swallow rehabilitation, and occupational therapy with lymphedema management and physical therapy. Efforts have been made to better understand, categorize, and strategize the intensive self-management protocols to improve quality of life of head and neck cancer survivors [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
         Post-therapy survivor care plans should be formulated to organize adequate support and rehabilitation to the head and neck cancer survivors. A prospective, randomized, controlled trial of the H&amp;N Cancer Survivor Self-management Care Plan (HNCP) involving pre- and post-intervention assessments showed improved quality of life of the survivors with unique needs by means of a tailored self-management care plan developed upon completion of treatment, delivered by trained oncology nurses [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
         Communications and coordination of care between the oncology team, the primary care clinician, the dentist, and any specialists involved in the management of the patient is recommended throughout the treatment and in the post-treatment period. Specific efforts should be made to include caregivers and spouses in the head and neck survivorship plans [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
         Several support groups and support sites are available to help guide head and neck cancer survivors and their treating clinicians in the management of late treatment-related complications [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2533290968">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">
          "Society guideline links: Head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2055114433">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83256.html" rel="external">
          "Patient education: Throat cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H590112183">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – There are more than half a million survivors who have been cured of head and neck cancer in the United States. The steady increase in the rate of head and neck cancer survivors is likely due to advances in treatment, decrease in smoking rates, and the improved prognosis of oropharyngeal carcinomas associated with human papillomavirus (HPV) infection. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of HNSCC depends on stage at presentation and the site of involvement. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stage I or II disease
         </strong>
         – Five-year overall survival in patients with stage I or II disease is approximately 70 to 90 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stage III or IV disease
         </strong>
         – The prognosis is poorer for patients who present with more advanced (stage III or IV) disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HPV associated cancer
         </strong>
         – For patients with human papillomavirus (HPV) associated locoregionally advanced disease, long-term survival rates are higher than those without HPV associated disease. (See
         <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">
          "Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance
         </strong>
         – In general, the intensity of follow-up is greatest in the first two to four years following diagnosis, since approximately 80 to 90 percent of all recurrences occur within this timeframe. However, patients should continue to be followed beyond five years because of the risk of late complications, as well as the risk of late recurrence or second malignancies. This may be especially important for patients without human papillomavirus (HPV) associated oropharyngeal cancers. (See
         <a class="local">
          'Guidelines for follow-up, surveillance, and secondary prevention in the long-term survivor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of subsequent primary cancers
         </strong>
         – Survivors should be routinely counseled for smoking and alcohol cessation, as subsequent primary cancers related to smoking and alcohol exposure have been reported in up to 20 percent of head and neck cancer survivors. (See
         <a class="local">
          'Subsequent primary cancers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral health and dental complications
         </strong>
         – Dental care and follow-up of oral health are very important, especially after radiation therapy to the head and neck area. Poor oral hygiene and dental health decline could lead to significant compromise in quality of life of the long-term head and neck cancer survivors. (See
         <a class="local">
          'Dental complications and oral health'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Worsening of dental health after treatment is common and is mostly as a result of dry mouth or "xerostomia" from head and neck radiation. (See
         <a class="local">
          'Xerostomia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other common complications include mucosal sensitivity, malocclusion of teeth or dental prosthesis (dentures), osteoradionecrosis, and trismus. (See
         <a class="local">
          'Osteoradionecrosis'
         </a>
         above and
         <a class="local">
          'Trismus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysphagia
         </strong>
         – Patients treated for HNSCC can experience dysphagia during treatment and as both an acute and long-term complication. Even for patients who present with longstanding dysphagia, we believe there is a role for cancer rehabilitation, including speech and language therapists. Despite preventive measures employed prior to and/or during treatment, 10 to 25 percent of HNSCC survivors become feeding tube-dependent for life. (See
         <a class="local">
          'Dysphagia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuromuscular toxicity
         </strong>
         – Several neuromuscular complications may occur in long-term HNSCC survivors. (See
         <a class="local">
          'Neuromuscular toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Specific toxicities
         </strong>
         – These include speech difficulties, chronic pain, ototoxicity, and/or peripheral or autonomic neuropathies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – For many of these concerns, rehabilitation that involves speech and physical therapists is an important part of management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Musculoskeletal complications
         </strong>
         – Lymphedema involving the neck may present as a late complication, especially in patients who underwent a neck dissection or RT. (See
         <a class="local">
          'Lymphedema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, neck stiffness is a common complaint that is encountered in clinic. (See
         <a class="local">
          'Neck stiffness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial issues
         </strong>
         – Survivors of HNSCC are at risk for psychosocial issues related to body image, speech unintelligibility, food-related lifestyle limitations, and sexual health. In addition, they are at high risk for mental health disorders, including depression, anxiety, and suicide. Fear of recurrence and fear regarding secondary cancers add to the burden of survivorship. Clinicians should be aware of these issues and regularly screen for them in follow-up to ensure that these patients get the support and counseling necessary. (See
         <a class="local">
          'Psychosocial issues'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Cancer Institute, National Institutes of Health. Head and neck cancer. https://www.cancer.gov/types/head-and-neck/hp (Accessed on July 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359:1143.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on July 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen EE, LaMonte SJ, Erb NL, et al. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin 2016; 66:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman BR, Goldenberg D, Givi B, Education Committee of American Head and Neck Society (AHNS). AHNS Series--Do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors. Head Neck 2016; 38:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auger S, Davis A, Rosenberg AJ. Recommendations for Care of Survivors of Head and Neck Cancer. JAMA 2022; 328:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caini S, Del Riccio M, Vettori V, et al. Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis. Br J Cancer 2022; 127:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayne ST, Cartmel B, Kirsh V, Goodwin WJ Jr. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 2009; 18:3368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke L, Miller LA, Saad A, Abraham J. Smoking behaviors among cancer survivors: an observational clinical study. J Oncol Pract 2009; 5:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013; 24:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiller U, Inhestern J, Burger U, et al. Predictors of post-treatment smoking and drinking behavior of head and neck cancer survivors: results of a population-based survey. Eur Arch Otorhinolaryngol 2016; 273:3337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowder SL, Douglas KG, Frugé AD, et al. Head and neck cancer survivors' preferences for and evaluations of a post-treatment dietary intervention. Nutr J 2019; 18:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies. Cancer Med 2015; 4:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sammut L, Fraser LR, Ward MJ, et al. Participation in sport and physical activity in head and neck cancer survivors: associations with quality of life. Clin Otolaryngol 2016; 41:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel SR, Maiya AG, Fernandes DJ, et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019; 27:3913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 2005; 115:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funk GF, Karnell LH, Christensen AJ. Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2012; 138:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Deiry M, Funk GF, Nalwa S, et al. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg 2005; 131:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payakachat N, Ounpraseuth S, Suen JY. Late complications and long-term quality of life for survivors (&gt;5 years) with history of head and neck cancer. Head Neck 2013; 35:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijers OB, Levendag PC, Braaksma MM, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 2002; 24:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AM, Daly ME, Vazquez E, et al. Depression among long-term survivors of head and neck cancer treated with radiation therapy. JAMA Otolaryngol Head Neck Surg 2013; 139:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxi SS, Pinheiro LC, Patil SM, et al. Causes of death in long-term survivors of head and neck cancer. Cancer 2014; 120:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CC, Lee WT, Hsiao JR, et al. Oral hygiene and the overall survival of head and neck cancer patients. Cancer Med 2019; 8:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haynes DA, Vanison CC, Gillespie MB. The Impact of Dental Care in Head and Neck Cancer Outcomes: A Systematic Review and Meta-Analysis. Laryngoscope 2022; 132:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly TE, Drane JB, MacComb WS. Management of problems of the teeth and jaw in patients undergoing irradiation. Am J Surg 1972; 124:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiot JC, Schraub S, Bone MC, et al. Dental preservation in patients irradiated for head and neck tumours: A 10-year experience with topical fluoride and a randomized trial between two fluoridation methods. Radiother Oncol 1983; 1:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon IL, Starcke EN, Wescott WB. Effect of radiotherapy on whole saliva flow. J Dent Res 1977; 56:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thariat J, De Mones E, Darcourt V, et al. [Teeth and irradiation in head and neck cancer]. Cancer Radiother 2010; 14:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy BA, Dietrich MS, Wells N, et al. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck 2010; 32:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White JM, Panchal NH, Wehler CJ, et al. Department of Veterans Affairs Consensus: Preradiation dental treatment guidelines for patients with head and neck cancer. Head Neck 2019; 41:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. Int J Radiat Oncol Biol Phys 2003; 56:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25:4873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin A, Kim HM, Terrell JE, et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003; 57:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 58:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao M, Karnell LH, Funk GF, et al. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 69:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AM, Daly ME, Farwell DG, et al. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. JAMA Otolaryngol Head Neck Surg 2014; 140:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed M, Hansen VN, Harrington KJ, Nutting CM. Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Med Dosim 2009; 34:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int J Oral Maxillofac Surg 2011; 40:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bensadoun RJ, Riesenbeck D, Lockhart PB, et al. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 2010; 18:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dijkstra PU, Huisman PM, Roodenburg JL. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 2006; 35:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009; 73:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartl DM, Cohen M, Juliéron M, et al. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol Head Neck Surg 2008; 138:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua DT, Lo C, Yuen J, Foo YC. A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am J Clin Oncol 2001; 24:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauloski BR, Rademaker AW, Logemann JA, et al. Pretreatment swallowing function in patients with head and neck cancer. Head Neck 2000; 22:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001; 127:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonelli M, Ruoppolo G, de Vincentiis M, et al. Swallowing ability and chronic aspiration after supracricoid partial laryngectomy. Otolaryngol Head Neck Surg 2010; 142:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBride SM, Parambi RJ, Jang JW, et al. Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: long-term dysphagia and tumor control outcomes. Head Neck 2014; 36:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JJ, Goldsmith TA, Holman AS, et al. Pharyngoesophageal stricture after treatment for head and neck cancer. Head Neck 2012; 34:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang TL, Chien CY, Tsai WL, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck 2016; 38 Suppl 1:E1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nutting C, Rooney K, Foran B, et al. Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer. J Clin Oncol 2020; 15S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutcheson KA, Lewin JS, Barringer DA, et al. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer 2012; 118:5793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bressmann T, Sader R, Whitehill TL, Samman N. Consonant intelligibility and tongue motility in patients with partial glossectomy. J Oral Maxillofac Surg 2004; 62:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stelzle F, Maier A, Nöth E, et al. Automatic quantification of speech intelligibility in patients after treatment for oral squamous cell carcinoma. J Oral Maxillofac Surg 2011; 69:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun J, Weng Y, Li J, et al. Analysis of determinants on speech function after glossectomy. J Oral Maxillofac Surg 2007; 65:1944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys 2010; 76:S64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallis A, Goumas PD, Mastronikolis NS, et al. Factors influencing quality of life after total laryngectomy: a study of 92 patients. Eur Rev Med Pharmacol Sci 2011; 15:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendenhall WM, Morris CG, Stringer SP, et al. Voice rehabilitation after total laryngectomy and postoperative radiation therapy. J Clin Oncol 2002; 20:2500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewin JS, Hutcheson KA, Barringer DA, et al. Customization of the voice prosthesis to prevent leakage from the enlarged tracheoesophageal puncture: results of a prospective trial. Laryngoscope 2012; 122:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boscolo-Rizzo P, Zanetti F, Carpené S, Da Mosto MC. Long-term results with tracheoesophageal voice prosthesis: primary versus secondary TEP. Eur Arch Otorhinolaryngol 2008; 265:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern Y, Marshak G, Shpitzer T, et al. Vocal cord palsy: possible late complication of radiotherapy for head and neck cancer. Ann Otol Rhinol Laryngol 1995; 104:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaruchinda P, Jindavijak S, Singhavarach N. Radiation-related vocal fold palsy in patients with head and neck carcinoma. J Med Assoc Thai 2012; 95 Suppl 5:S23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekbom DC, Garrett CG, Yung KC, et al. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults. Laryngoscope 2010; 120:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marunick M, Tselios N. The efficacy of palatal augmentation prostheses for speech and swallowing in patients undergoing glossectomy: a review of the literature. J Prosthet Dent 2004; 91:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieger J, Bohle Iii G, Huryn J, et al. Surgical reconstruction versus prosthetic obturation of extensive soft palate defects: a comparison of speech outcomes. Int J Prosthodont 2009; 22:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keereweer S, de Wilt JH, Sewnaik A, et al. Early and long-term morbidity after total laryngopharyngectomy. Eur Arch Otorhinolaryngol 2010; 267:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Gogh CD, Verdonck-de Leeuw IM, Boon-Kamma BA, et al. The efficacy of voice therapy in patients after treatment for early glottic carcinoma. Cancer 2006; 106:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer S, Meyer A, Fuchs M, et al. Motivation as a predictor of speech intelligibility after total laryngectomy. Head Neck 2013; 35:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer S, Wollbrück D, Dietz A, et al. Speech rehabilitation during the first year after total laryngectomy. Head Neck 2013; 35:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med 2007; 8:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckwalter AE, Karnell LH, Smith RB, et al. Patient-reported factors associated with discontinuing employment following head and neck cancer treatment. Arch Otolaryngol Head Neck Surg 2007; 133:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang C, Wang H, Wang Q, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States. JAMA Oncol 2019; 5:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulff-Burchfield E, Dietrich MS, Ridner S, Murphy BA. Late systemic symptoms in head and neck cancer survivors. Support Care Cancer 2019; 27:2893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010; 28:2565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumacher LD, Sargi ZB, Masforroll M, et al. Long-term opioid use in curative-intent radiotherapy: One-Year outcomes in head/neck cancer patients. Head Neck 2020; 42:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007; 25:3759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keilty D, Khandwala M, Liu ZA, et al. Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. J Clin Oncol 2021; 39:3813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995; 6:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007; :CD005228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharabi Y, Dendi R, Holmes C, Goldstein DS. Baroreflex failure as a late sequela of neck irradiation. Hypertension 2003; 42:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elerding SC, Fernandez RN, Grotta JC, et al. Carotid artery disease following external cervical irradiation. Ann Surg 1981; 194:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng J, Ridner SH, Murphy BA. Lymphedema in patients with head and neck cancer. Oncol Nurs Forum 2011; 38:E1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith BG, Lewin JS. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2010; 18:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy BA, Gilbert J. Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. Semin Radiat Oncol 2009; 19:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piso DU, Eckardt A, Liebermann A, et al. Early rehabilitation of head-neck edema after curative surgery for orofacial tumors. Am J Phys Med Rehabil 2001; 80:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goguen LA, Chapuy CI, Li Y, et al. Neck dissection after chemoradiotherapy: timing and complications. Arch Otolaryngol Head Neck Surg 2010; 136:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah S, Har-El G, Rosenfeld RM. Short-term and long-term quality of life after neck dissection. Head Neck 2001; 23:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26:3582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RJ, Chepeha JC, Teknos TN, et al. Development and validation of the neck dissection impairment index: a quality of life measure. Arch Otolaryngol Head Neck Surg 2002; 128:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGarvey AC, Chiarelli PE, Osmotherly PG, Hoffman GR. Physiotherapy for accessory nerve shoulder dysfunction following neck dissection surgery: a literature review. Head Neck 2011; 33:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgier C, Auperin A, Rivera S, et al. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. Int J Radiat Oncol Biol Phys 2019; 104:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan HK, Bernstein LJ, Brown J, et al. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 81:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zer A, Pond GR, Razak ARA, et al. Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2018; 144:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30:3752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 2006; 18:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamdi T, Latta S, Jallad B, et al. Cisplatin-induced renal salt wasting syndrome. South Med J 2010; 103:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taberna M, Inglehart RC, Pickard RK, et al. Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer. Cancer 2017; 123:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjordal K, Ahlner-Elmqvist M, Hammerlid E, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope 2001; 111:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxi SS, Shuman AG, Corner GW, et al. Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know. Head Neck 2013; 35:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fingeret MC, Hutcheson KA, Jensen K, et al. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head Neck 2013; 35:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhoten BA, Murphy B, Ridner SH. Body image in patients with head and neck cancer: a review of the literature. Oral Oncol 2013; 49:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veer V, Kia S, Papesch M. Anxiety and depression in head and neck out-patients. J Laryngol Otol 2010; 124:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry M, Rosberger Z, Bertrand L, et al. Prevalence and Risk Factors of Suicidal Ideation among Patients with Head and Neck Cancer: Longitudinal Study. Otolaryngol Head Neck Surg 2018; 159:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osazuwa-Peters N, Simpson MC, Zhao L, et al. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer 2018; 124:4072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapoport Y, Kreitler S, Chaitchik S, et al. Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis. Ann Oncol 1993; 4:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendal WS. Suicide and cancer: a gender-comparative study. Ann Oncol 2007; 18:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misono S, Weiss NS, Fann JR, et al. Incidence of suicide in persons with cancer. J Clin Oncol 2008; 26:4731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vartanian JG, Carvalho AL, Toyota J, et al. Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncol 2010; 46:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells M, Swartzman S, Lang H, et al. Predictors of quality of life in head and neck cancer survivors up to 5 years after end of treatment: a cross-sectional survey. Support Care Cancer 2016; 24:2463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross S, Mosher CE, Ronis-Tobin V, et al. Psychosocial adjustment of family caregivers of head and neck cancer survivors. Support Care Cancer 2010; 18:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seaman AT, Seligman KL, Nguyen KK, et al. Characterizing head and neck cancer survivors' discontinuation of survivorship care. Cancer 2022; 128:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rennemo E, Zätterström U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 2008; 118:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris LG, Sikora AG, Patel SG, et al. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011; 29:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlstrom KR, Li G, Tortolero-Luna G, et al. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck 2011; 33:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsythe LP, Alfano CM, Leach CR, et al. Who provides psychosocial follow-up care for post-treatment cancer survivors? A survey of medical oncologists and primary care physicians. J Clin Oncol 2012; 30:2897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bond SM, Schumacher K, Dietrich MS, et al. Initial psychometric testing of the Head and Neck Cancer Patient Self-Management Inventory (HNC-PSMI). Eur J Oncol Nurs 2020; 47:101751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner J, Yates P, Kenny L, et al. The ENHANCES study--Enhancing Head and Neck Cancer patients' Experiences of Survivorship: study protocol for a randomized controlled trial. Trials 2014; 15:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nekhlyudov L, Lacchetti C, Davis NB, et al. Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. J Clin Oncol 2017; 35:1606.
          </a>
         </li>
         <li class="breakAll">
          OncoLink. Head and Neck Cancer Survivorship. https://www.oncolink.org/cancers/head-and-neck/head-and-neck-cancer-survivorship.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 89977 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cancer.gov/types/head-and-neck/hp" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Cancer Institute, National Institutes of Health. Head and neck cancer. https://www.cancer.gov/types/head-and-neck/hp (Accessed on July 04, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18784104" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recent advances in head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18784104" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recent advances in head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27002678" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : American Cancer Society Head and Neck Cancer Survivorship Care Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916656" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : AHNS Series--Do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36201185" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recommendations for Care of Survivors of Head and Neck Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35999273" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19959684" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20856708" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Smoking behaviors among cancer survivors: an observational clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22910838" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Light alcohol drinking and cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874733" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of post-treatment smoking and drinking behavior of head and neck cancer survivors: results of a population-based survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31506077" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Head and neck cancer survivors' preferences for and evaluations of a post-treatment dietary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26471010" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26212795" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Participation in sport and physical activity in head and neck cancer survivors: associations with quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30919154" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15805880" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Dental status and quality of life in long-term head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22248560" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-term health-related quality of life in survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230590" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22807083" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Late complications and long-term quality of life for survivors (&gt;5 years) with history of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12203798" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23949013" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Depression among long-term survivors of head and neck cancer treated with radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24863390" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Causes of death in long-term survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30865385" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Oral hygiene and the overall survival of head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33635587" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Impact of Dental Care in Head and Neck Cancer Outcomes: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5076170" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Management of problems of the teeth and jaw in patients undergoing irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6680214" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dental preservation in patients irradiated for head and neck tumours: A 10-year experience with topical fluoride and a randomized trial between two fluoridation methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/268349" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of radiotherapy on whole saliva flow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189430" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : [Teeth and irradiation in head and neck cancer].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19626644" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30620438" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Department of Veterans Affairs Consensus: Preradiation dental treatment guidelines for patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936542" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term parotid gland function after radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12788192" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17289292" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17971582" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12909216" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14967418" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17689885" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24337483" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19647632" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21115324" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20213237" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A systematic review of trismus induced by cancer therapies in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16280237" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Criteria for trismus in head and neck oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18707827" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18359354" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Botulinum toxin for radiation-induced facial pain and trismus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11474263" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A pilot study of pentoxifylline in the treatment of radiation-induced trismus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10897107" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pretreatment swallowing function in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448365" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20493361" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Swallowing ability and chronic aspiration after supracricoid partial laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23729221" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: long-term dysphagia and tumor control outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21953721" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pharyngoesophageal stricture after treatment for head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26041548" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23640737" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Late dysphagia after radiotherapy-based treatment of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15015161" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Consonant intelligibility and tongue motility in patients with partial glossectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21216061" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Automatic quantification of speech intelligibility in patients after treatment for oral squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17884520" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Analysis of determinants on speech function after glossectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20171520" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Radiation dose-volume effects in the larynx and pharynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21845804" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Factors influencing quality of life after total laryngectomy: a study of 92 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12011128" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Voice rehabilitation after total laryngectomy and postoperative radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753122" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Customization of the voice prosthesis to prevent leakage from the enlarged tracheoesophageal puncture: results of a prospective trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17713782" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-term results with tracheoesophageal voice prosthesis: primary versus secondary TEP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7717620" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vocal cord palsy: possible late complication of radiotherapy for head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22934441" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Radiation-related vocal fold palsy in patients with head and neck carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20213793" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739896" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The efficacy of palatal augmentation prostheses for speech and swallowing in patients undergoing glossectomy: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19918590" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Surgical reconstruction versus prosthetic obturation of extensive soft palate defects: a comparison of speech outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20372916" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Early and long-term morbidity after total laryngopharyngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323175" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The efficacy of voice therapy in patients after treatment for early glottic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22733689" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Motivation as a predictor of speech intelligibility after total laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23169434" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Speech rehabilitation during the first year after total laryngectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17305690" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Chronic pain in the cancer survivor: a new frontier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520760" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Patient-reported factors associated with discontinuing employment following head and neck cancer treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31219506" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30554277" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Late systemic symptoms in head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20406930" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31785054" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Long-term opioid use in curative-intent radiotherapy: One-Year outcomes in head/neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17704425" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34570616" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17228018" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7670134" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Cisplatin-associated neurotoxicity: can it be prevented?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18346229" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Chemotherapy-induced neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17253547" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Interventions for preventing neuropathy caused by cisplatin and related compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12782644" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Baroreflex failure as a late sequela of neck irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7294930" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Carotid artery disease following external cervical irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21186146" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Lymphedema in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463478" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Lymphedema management in head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19028344" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11277132" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Early rehabilitation of head-neck edema after curative surgery for orofacial tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079159" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Neck dissection after chemoradiotherapy: timing and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11754499" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Short-term and long-term quality of life after neck dissection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559875" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11784253" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Development and validation of the neck dissection impairment index: a quality of life measure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20222043" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Physiotherapy for accessory nerve shoulder dysfunction following neck dissection surgery: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30776452" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20708851" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29167901" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7193726" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23008318" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17100159" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Magnesium depletion in patients receiving cisplatin-based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20622742" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Cisplatin-induced renal salt wasting syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28195638" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Significant changes in sexual behavior after a diagnosis of human papillomavirus-positive and human papillomavirus-negative oral cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568582" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23169350" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431304" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23683468" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Body image in patients with head and neck cancer: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20307357" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Anxiety and depression in head and neck out-patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29865939" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Prevalence and Risk Factors of Suicidal Ideation among Patients with Head and Neck Cancer: Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30335190" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Suicide risk among cancer survivors: Head and neck versus other cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435366" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17053045" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Suicide and cancer: a gender-comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18695257" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Incidence of suicide in persons with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415426" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004135" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Employment and return to work in head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26660345" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Predictors of quality of life in head and neck cancer survivors up to 5 years after end of treatment: a cross-sectional survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390870" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Psychosocial adjustment of family caregivers of head and neck cancer survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34460935" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Characterizing head and neck cancer survivors' discontinuation of survivorship care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18496157" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189382" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20737488" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22778322" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Who provides psychosocial follow-up care for post-treatment cancer survivors? A survey of medical oncologists and primary care physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32521434" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Initial psychometric testing of the Head and Neck Cancer Patient Self-Management Inventory (HNC-PSMI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24885486" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The ENHANCES study--Enhancing Head and Neck Cancer patients' Experiences of Survivorship: study protocol for a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28240970" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
